BridgeBio Pharma, Inc. Revenue Breakdown
No Revenue Breakdown for BBIO on this site yet.
- 2025-12-31: Others Not split by product in the filing$502.08M100.00%; Total revenue $502.08M.
- 2024-12-31: Others Not split by product in the filing$221.90M100.00%; Total revenue $221.90M.
- 2023-12-31: Others Not split by product in the filing$9.30M100.00%; Total revenue $9.30M.
- 2022-12-31: Others Not split by product in the filing$77.65M100.00%; Total revenue $77.65M.
Source checked: the stored Revenue Breakdown page for BBIO.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | Not split by product in the filing $502.08M 100.00% | $502.08M |
| 2024-12-31 | Not split by product in the filing $221.90M 100.00% | $221.90M |
| 2023-12-31 | Not split by product in the filing $9.30M 100.00% | $9.30M |
| 2022-12-31 | Not split by product in the filing $77.65M 100.00% | $77.65M |
| 2021-12-31 | Not split by product in the filing $69.72M 100.00% | $69.72M |
| 2020-12-31 | Not split by product in the filing $8.25M 100.00% | $8.25M |
| 2019-12-31 | Not split by product in the filing $40.56M 100.00% | $40.56M |
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2026-06-30 | Not split by product $243.68M 100.00% | $243.68M |
| 2026-03-31 | Not split by product $194.51M 100.00% | $194.51M |
| 2025-12-31 | Not split by product $154.18M 100.00% | $154.18M |
| 2025-09-30 | Not split by product $120.70M 100.00% | $120.70M |
| 2025-06-30 | Not split by product $110.56M 100.00% | $110.56M |
| 2025-03-31 | Not split by product $116.63M 100.00% | $116.63M |
| 2024-12-31 | Not split by product $5.88M 100.00% | $5.88M |
| 2024-09-30 | Not split by product $2.73M 100.00% | $2.73M |
| 2024-06-30 | Not split by product $2.17M 100.00% | $2.17M |
| 2024-03-31 | Not split by product $211.12M 100.00% | $211.12M |
| 2023-12-31 | Not split by product $1.75M 100.00% | $1.75M |
| 2023-09-30 | Not split by product $4.09M 100.00% | $4.09M |
| 2023-06-30 | Not split by product $1.64M 100.00% | $1.64M |
| 2023-03-31 | Not split by product $1.83M 100.00% | $1.83M |
| 2022-12-31 | Not split by product $1.87M 100.00% | $1.87M |
| 2022-09-30 | Not split by product $338.00K 100.00% | $338.00K |
| 2022-06-30 | Not split by product $73.75M 100.00% | $73.75M |
| 2022-03-31 | Not split by product $1.69M 100.00% | $1.69M |
| 2021-12-31 | Not split by product $12.89M 100.00% | $12.89M |
| 2021-09-30 | Not split by product $2.34M 100.00% | $2.34M |
| 2021-06-30 | Not split by product $54.02M 100.00% | $54.02M |
| 2021-03-31 | Not split by product $462.00K 100.00% | $462.00K |
| 2020-12-31 | Not split by product $122.00K 100.00% | $122.00K |
| 2020-09-30 | Not split by product $8.13M 100.00% | $8.13M |
| 2019-12-31 | Not split by product $13.82M 100.00% | $13.82M |
| 2019-09-30 | Not split by product $26.74M 100.00% | $26.74M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |